Plain-English translation of NCT07680946 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 research study testing a medication called in people who have schizophrenia that hasn't responded well to standard treatments. is an antibody-based medication — a type of biologic therapy — given by intravenous (IV) infusion. The study aims to see whether this medication can safely reduce the positive and negative symptoms of schizophrenia.
Many people with schizophrenia struggle to find treatments that work for them, especially when standard antipsychotic medications aren't effective enough. This medication represents a newer approach, and researchers want to understand whether it could be a helpful option for people with treatment-resistant schizophrenia.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive intravenous infusions of the medication at a clinic or research center. You'll have regular visits to receive the treatment and be monitored by the research team to check how you're responding and watch for any side effects. The study is designed to assess whether the medication helps reduce your symptoms compared to your baseline.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States